Investor Presentaiton

26 Sartorius Group High innovation dynamics in Biopharmal 888 昌 Development of new drugs and vaccines must be accelerated, e.g. through more automation Increased efficiency possible in the production of 'classic' biopharmaceuticals and biosimilars New tools and methods required e.g. for novel cell and gene therapies Future drug manufacturing is more automated, intensified and scalable SARTORIUS

View entire presentation